Vimarsana
Biggest News Aggregation in the World

Page 7 - Dee Smith News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dee Smith. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dee Smith Today - Breaking & Trending Today

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 07, 2023 -- Fulcrum Therapeutics, Inc.® , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases,...

At 81, the Queen of Carson City's Burger King serves full-time job with a smile - Vimarsana News

At 81, the Queen of Carson City's Burger King serves full-time job with a smile

Once upon a time, the American Dream for older Baby Boomers was to retire at age 65. That dream was not to come true for many who had been working since high school and surviving several depressions that kept them worrying about keeping a stable roof over their head and food on the table.

Mount Vernon News - Vimarsana News

Mount Vernon News

Mount Vernon News covers local news, sports, events and all things Knox County.

Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) - Vimarsana News

Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)

Project Mercury unites patients, industry, research and clinical communities in groundbreaking initiativeRANDOLPH, Mass. and CAMBRIDGE, Mass., June 20, 2023 -- Today on World FSHD Day, the FSHD... | June 20, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq - Vimarsana News

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq

CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...